Radiosynovectomy.
- Author:
Deog Yoon KIM
1
Author Information
- Publication Type:Review
- Keywords: radionuclide therapy; radiosynovectomy; rheumatoid arthritis; hemophilia
- MeSH: Arthritis; Arthritis, Rheumatoid; Blood Coagulation Factors; Citric Acid; Europe; Hemophilia A; Hemorrhage; Humans; Joints; Korea; Radioisotopes; Radiopharmaceuticals; Synovitis
- From:Nuclear Medicine and Molecular Imaging 2006;40(2):127-131
- CountryRepublic of Korea
- Language:Korean
- Abstract: Radiosynovectomy has been used as an effective treatment in patients with resistant synovitis after failure of long-term medication and intraarticular steroid injection. Although 90Y silicate/citrate, 186Re sulfide, and 169Er citrate were approved in Europe for the appropriate radiopharmaceuticals for radiosynovectomy, other radionuclides such as 32P-chromic phosphate, 165Dy-ferric hydroxide macroaggregate, 188Rh-microspheres, 153Sm-particulate, and 166Ho-ferric hydroxide macroaggregate have been used in many countries. Reported success rates range from 40% to 90% for the different joints and underlying disease. In Korea, 188Re-tin-colloid and 166Ho-chitosan complex are now using as the major radionuclides in radiosynovectomy with good clinical results. A study on radiation synovectomy using 188Re-tin-colloid for patients with Korean rheumatoid arthritis shows the treatment resulted in the improvement of arthritis and well tolerated. In our study, the radiosynovectomy with 166Ho-chitosan complex in 53 hemophilic patients markedly decreased intra-articular bleeding frequency and need for coagulation factor. This review inculdes general priciples in the application of radiosynovectomy and the clinical experience in Korea.
